• Explore /
  • Poster
  • / SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.

SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.

Abstract Video & Slides Poster

Authors

null

Andre Rashad Kydd

Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD

Andre Rashad Kydd , Elias Chandran , Nicholas I. Simon , Saad Omar Atiq , Tzu-fang Wang , Lisa M. Cordes , Elizabeth Smith , Matthew Lindsley , Lisa Ley , Salah Boudjadi , Scot Anthony Niglio , Sally Weng , Ian Stukes , Md Shahid Sarwar , Rouf Banday , Dilara Akbulut , Sandeep Gurram , Bernadette Redd , Seth M. Steinberg , Andrea B Apolo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Other GU Kidney and Bladder Cancer

Clinical Trial Registration Number

NCT06161532

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4627)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4627

Abstract #

TPS4627

Poster Bd #

312a

Abstract Disclosures